Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

63%

5 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

3(50.0%)

Phase 3

2(33.3%)

N/A

1(16.7%)

6Total

Phase 4(3)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03201848Phase 4Active Not Recruiting

The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia

Role: lead

NCT02975661Unknown

Registry of Huaier Granule for Prevention of Recurrence and Metastasis of Gastrointestinal Cancer After Radical Surgery

Role: lead

NCT03332420Completed

The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome

Role: lead

NCT03198117Not ApplicableTerminated

Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT01760616Phase 4Terminated

Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy

Role: lead

NCT01770431Phase 4Completed

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy

Role: lead

NCT02796820Phase 3Unknown

Huaier Granule As Adjuvant Therapy for Colorectal Cancer After Radical Surgery

Role: collaborator

NCT02785146Phase 3Unknown

Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer

Role: collaborator

All 8 trials loaded